Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS

Liver International

Volumn 34, Issue 9, 2014, Pages 1428-1444

  Fitian, Asem I ^a   Nelson, David R ^a,b   Liu, Chen ^b   Xu, Yiling ^b   Ararat, Miguel ^b   Cabrera, Roniel ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cirrhosis; HCC; Liquid chromatography mass spectrometry; Metabolic profiling; Metabolomics

Indexed keywords

ACYLCARNITINE; AMINO ACID; BILE ACID; GLYCOCHOLIC ACID; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID; 12 HYDROXYICOSATETRAENOIC ACID; 15-HYDROXY-5,8,11,13-EICOSATETRAENOIC ACID; DICARBOXYLIC ACID; HYDROXYICOSATETRAENOIC ACID; SPHINGOSINE; XANTHINE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GAS CHROMATOGRAPHY; HEPATITIS C; HOMEOSTASIS; HUMAN; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; OXIDATIVE STRESS; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VIRUS HEPATITIS; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER NEOPLASMS; MASS FRAGMENTOGRAPHY; METABOLOME; MULTIVARIATE ANALYSIS; PHYSIOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; AMINO ACIDS; BILE ACIDS AND SALTS; CARCINOMA, HEPATOCELLULAR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DICARBOXYLIC ACIDS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEPATITIS C; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLOME; METABOLOMICS; MULTIVARIATE ANALYSIS; ROC CURVE; SPHINGOSINE; TANDEM MASS SPECTROMETRY; XANTHINE;

EID: 84908257789     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12541     Document Type: Article

References (57)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:1485-91.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-27.
3. Hussain SM, Semelka RC, Mitchell DG. MR imaging of hepatocellular carcinoma. Magn Reson Imaging Clin N Am 2002; 10: 31-52.
4. Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010; 52:132-41.
5. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry- based metabolomics. Mass Spectrom Rev 2007; 26: 51-78.
6. Yang Y, Li C, Nie X, et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magicangle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res 2007; 6: 2605-14.
7. Patterson AD, Maurhofer O, Beyoglu D, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 2011; 71: 6590-600.
8. Chen T, Xie G, Wang X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011; 10: M110. 004945
9. Wu FX, Wang Q, Zhang ZM, et al. Identifying serological biomarkers of hepatocellular carcinoma using surfaceenhanced laser desorption/ionization-time-of-flight mass spectroscopy. Cancer Lett 2009; 279: 163-70.
10. Cao H, Huang H, Xu W, et al. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. Anal Chim Acta 2011; 691: 68-75.
11. Gao H, Lu Q, Liu X, et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci 2009; 100: 782-5.
12. Wu H, Xue R, Dong L, et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 2009; 648: 98-104.
13. Soga T, Sugimoto M, Honma M, et al. Serum metabolomics reveals c-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol 2011; 55: 896-905.
14. Ressom HW, Xiao JF, Tuli L, et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta 2012; 743: 90-100.
15. Xiao JF, Varghese RS, Zhou B, et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J Proteome Res 2012; 11: 5914-23.
16. Wang B, Chen D, Chen Y, et al. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res 2012; 11: 1217-27.
17. Zhou L, Ding L, Yin P, et al. Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatographymass spectrometry. J Proteome Res 2012; 11: 5433-42.
18. Nahon P, Amathieu R, Triba MN, et al. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin Cancer Res 2012; 18: 6714-22.
19. Yin P, Wan D, Zhao C, et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 2009; 5: 868-76.
20. Li S, Liu H, Jin Y, et al. Metabolomics study of alcoholinduced liver injury and hepatocellular carcinoma xenografts in mice. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2369-75.
21. Budhu A, Roessler S, Zhao X, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 2013; 144: 1066-75.
22. Beyoglu D, Imbeaud S, Maurhofer O, et al. Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. Hepatology 2013; 58: 229-38.
23. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009; 81: 6656-67.
24. Wu JM, Skill NJ, Maluccio MA. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB 2010; 12: 625-36.
25. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996; 77: 2217-22.
26. Uderhardt S, Krönke G. 12/15-lipoxygenase during the regulation of inflammation, immunity, and self-tolerance. J Mol Med 2012; 90: 1247-56.
27. Liu B, Timar J, Howlett J, Diglio CA, Honn KV. Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C. Cell Regul 1991; 2: 1045-55.
28. Xu XM, Yuan GJ, Deng JJ, et al. Inhibition of 12-lipoxygenase reduces proliferation and induces apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Hepatobiliary Pancreat Dis Int 2012; 11: 193-202.
29. Wong BCY, Wang PW, Cho HC, et al12-Lipoxygenase inhibition induced apoptosis in human gastric cancer cells Carcinogenesis 2001; 22: 1349-54.
30. Chen YQ, Duniec ZM, Liu B, et al. Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res 1994; 54: 1574-9.
31. Ma J, Zhang L, Zhang J, et al15-Lipoxygenase-1/15-hydroxyeicosatetraenoic acid promotes hepatocellular cancer cells growth through protein kinase B heat shock protein 90 complex activation, Int J Biochem Cell Biol 2013; 45:1031-41.
32. Marra M, Sordelli IM, Lombardi A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma:an overview. J Transl Med 2011; 9: 171.
33. Lin CC, Yin MC. B vitamins deficiency and decreased anti-oxidative state in patients with liver cancer. Eur J Nutr 2007; 46: 293-9.
34. Stirpe F, Ravaioli M, Battelli MG, Musiani S, Grazi GL. Xanthine oxidoreductase activity in human liver disease. Am J Gastroenterol 2002; 97: 2079-85.
35. Shi DY, Xie FZ, Zhai C, et al. The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells. Mol Cancer 2009; 8: 32.
36. Li T, Zhao XP, Wang LY, et al. Glutathione s-transferase p1 correlated with oxidative stress in hepatocellular carcinoma. Int J Med Sci 2013; 10: 683-90.
37. Sherman M, Campbell JA, Titmuss SA, Kew MC, Kirsch RE. Glutathione S-transferase in human hepatocellular carcinoma. Hepatology 1983; 3: 170-6.
38. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013; 339: 211-214.
39. Chaneton B, Hillmann P, Zheng L, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 2012; 491: 458-62.
40. Jain M, Nilsson R, Sharma S, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012; 336: 1040-4.
41. Huang W, Chen C, Lin Y, Lin C. Apoptotic sphingolipid ceramide in cancer therapy. Journal of Lipids 2011; Article ID: 565316.
42. Yang L, Yue S, Yang L, et al. Sphingosine kinase/Sphingosine 1-phosphate (S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis. J Hepatol 2013; 59:114-23.
43. Morales A, París R, Villanueva A, et al. Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene 2007; 26: 905-16.
44. Mas VR, Maluf DG, Archer KJ, et al. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 2009; 15: 85-94.
45. Bao M, Chen Z, Xu Y, et al. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/ EDG1 axis in hepatocellular carcinoma. Liver Int 2012; 32:331-8.
46. Beljanski V, Knaak C, Zhuang Y, Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs 2011; 29: 1132-42.
47. Bedosa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3.
48. Vamecq J, Draye JP, Brison J. Rat liver metabolism of dicarboxylic acids. Am J Physiol 1989; 1: G680-8.
49. Meyer K, Jia Y, Cao WQ, Kashireddy P, Rao MS. Expression of peroxisome proliferator-activated receptor alpha, and PPARalpha regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-CoA oxidase null mice. Int J Oncol 2002; 21: 1175-80.
50. Lalwani ND, Reddy MK, Qureshi SA, Reddy JK. Development of hepatocellular carcinomas and increased peroxisomal fatty acid beta-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in the semipurified diet. Carcinogenesis 1981; 2: 645-50.
51. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 2001; 21: 193-230.
52. Barnes S, Gallo GA, Trash DB, Morris JS. Diagnositic value of serum bile acid estimations in liver disease. J Clin Pathol 1975; 28: 506-9.
53. Neale G, Lewis B, Weaver V, Panveliwalla D. Serum bile acids in liver disease. Gut 1971; 12: 145-52.
54. Festi D, MorselliLabate AM, Roda A, et al. Diagnostic effectiveness of serum bile acids in liver diseases as evaluated by multivariate statistical methods. Hepatology 1983; 3: 707-13.
55. Tytgat GN, Collen D, Verstraete M. Metabolism of fibrinogen in cirrhosis of the liver. J Clin Invest 1971; 50: 1690-701.
56. Amodio P, Angeli P, Merkel C, Menon F, Gatta A. Plasma carnitine levels in liver cirrhosis: relationship with nutritional status and liver damage. J Clin Chem Clin Biochem 1990; 2: 619-26.
57. Alonso de la Peña C, Rozas I, Alvarez-Prechous A, et al. Free carnitine and acylcarnitine levels in sera of alcoholics. Biochem Med Metab Biol 1990; 44: 77-83.